Hzymes Biotechnology Co., Ltd.
PrivateLast Round
Series C
Nov 5, 2021
Est. Valuation
$750.24M
Total Funding Raised
$125.19M
Company Overview
Hzymes Biotechnology Co., Ltd. operates in Healthcare & Life Sciences and is based in Wuhan. Its latest recorded funding round was a Series C round in November 2021.
Hzymes Biotechnology Co., Ltd. is a biotechnology company that specializes in the research, development, and production of enzyme-based raw materials for the biopharmaceutical and in vitro diagnostics industries.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hzymes Biotechnology Co., Ltd. Comparables
Compare Hzymes Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novoprotein Scientific Inc. | 81% | |
| Yeasen Biotechnology (Shanghai) Co., Ltd. | 81% | |
| Nanjing Vazyme Biotech Co Ltd | 78% |
For institutional investors. Book with your work email.
Hzymes Biotechnology Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 5, 2021 | ||||
| VC Round | Jul 1, 2020 | ||||
| Series B | Nov 1, 2019 | ||||
| Series A | Jul 27, 2018 | ||||
| Angel | Dec 1, 2015 |
For institutional investors. Book with your work email.
Hzymes Biotechnology Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GL Capital Group | Series C |
| Guoke Jiahe Capital | Series C |
| Shanghai Science and Technology Innovation Group | Series C |
| GF Venture Capital | VC Round, Series C |
| Wuhan Guanggu Talent Fund | Angel |
| Sanze Venture Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 1, 2020
GF Venture Capital participated in the round.
- Jul 27, 2018
Raised Series A with Sanze Venture Capital participating.
For institutional investors. Book with your work email.
Hzymes Biotechnology Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Hzymes Biotechnology Co., Ltd.'s valuation, stock price, and market status.
Is Hzymes Biotechnology Co., Ltd. a public or private company?
Hzymes Biotechnology Co., Ltd. is a private company.
What is the current stock price of Hzymes Biotechnology Co., Ltd.?
Hzymes Biotechnology Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Hzymes Biotechnology Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hzymes Biotechnology Co., Ltd. worth (valuation)?
Hzymes Biotechnology Co., Ltd.'s valuation is estimated at $750.2M based on funding round data.
Can I buy Hzymes Biotechnology Co., Ltd. stock?
Hzymes Biotechnology Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hzymes Biotechnology Co., Ltd.'s last funding round?
Hzymes Biotechnology Co., Ltd.'s most recent funding round was Series C on November 5, 2021.
Who are the main investors in Hzymes Biotechnology Co., Ltd.?
Key investors in Hzymes Biotechnology Co., Ltd. include GL Capital Group.
Will Hzymes Biotechnology Co., Ltd. IPO soon?
No public IPO plans have been announced for Hzymes Biotechnology Co., Ltd..
How can I track Hzymes Biotechnology Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Hzymes Biotechnology Co., Ltd.'s shares on secondary markets.